Skip to main content
TipRanks
Go Ultimate75% OFF

Sonova Holding AG (SONVY) AI Stock Analysis

32 Followers
SONVY

Sonova Holding AG

(Other OTC:SONVY)

Select Model
Rating:73Outperform
Price Target:$76.00â–²(11.29% Upside)
Action:upgraded
Date:11/12/26

With an overall score of 73, SONVY exhibits robust operational momentum and fundamental strength, led by a highly positive earnings outlook, successful product launches, and a cash-rich balance sheet. Technically, the stock remains in a strong long-term bullish trend with oversold signals suggesting near-term upside. However, the score is notably constrained by an expensive valuation profile and ongoing challenges in its cochlear implant segment.

Positive Factors
Sustained market-share gainsRepeated wholesale growth and 11 consecutive quarters of share gains indicate improving competitive position rather than a single launch benefit. A larger installed and channel footprint can support future fittings, upgrades, recurring accessories, and stronger negotiating leverage.
Negative Factors
Cochlear implant weakness and regulatory uncertaintyThe cochlear implant segment is currently reducing growth and earnings support, with lower systems and upgrades compounded by China VBP effects. Uncertain U.S. approval timing for Integro could prolong the weakness and delay a recovery in this business.

Sonova Holding AG (SONVY) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%50%SONVY+42.38%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$20.27B
Dividend Yield
1.70%
Average Volume (3M)
15.08K
Price to Earnings (P/E)
34.5
Beta (1Y)
0.87
Revenue Growth
0.68%
EPS Growth
2.45%
Country
US
Employees
18,447
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Sonova Holding AG Business Overview & Revenue Model

Company Description

Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range in...

How the Company Makes Money

Sonova makes money by selling hearing care products and services through two primary channels: (1) product sales to third-party providers and (2) direct-to-consumer sales through company-owned or affiliated retail clinics. 1) Hearing Instruments (hea...

Sonova Holding AG Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q2-2027)|% Change Since:0.50%|Next Earnings Date:May 18, 2027
Earnings Call SentimentPositive

The call was strongly positive overall. Sonova reported broad-based sales growth, continued market share gains, significant core EBIT and cash-flow growth, improved returns, strong early product reception and higher full-year guidance. The main challenges were the 10% decline in cochlear implant sales, uncertain U.S. regulatory timing for Integro, slower U.S. and Canadian retail performance, efficiency concerns around sales and marketing spending, discontinued-operation impairment charges and expected market moderation after launch-related stocking. Management nevertheless expressed confidence in continued share gains and execution in the second half.

Positive Updates

Strong First-Half Group Performance
Group sales reached CHF 1.8 billion, increasing 7.5% in local currencies and 6.7% in Swiss francs. Organic growth contributed 7 percentage points, M&A contributed 0.5 percentage points, and foreign exchange reduced reported growth by 0.8 percentage points.

Negative Updates

Cochlear Implant Sales Declined
Cochlear implant sales declined 10% in the first half. Systems were down 3% and upgrades were down 27%, reflecting China VBP, lower system sales in the United States and significantly lower upgrade sales.

Company Guidance

Sonova now expects global hearing aid market growth of 3% to 5% during the current financial year, consolidated sales growth of 6% to 8% compared with 5% to 8% previously, and core EBIT growth of 10% to 13% compared with 7% to 10% previously; currency translation is expected to be broadly neutral for sales and core EBIT for the full year. The company expects to accelerate strategic investments in the second half by low double-digit CHF million amount, within its midterm 5% to 10% sales growth target, while cochlear implant sales are expected to show an improvement in the second half subject to the timing of regulatory approval in the United States. Sonova remains within its expected CHF 35 million to CHF 40 million for noncore costs, is on track to invest around CHF 80 million to CHF 100 million annually in bolt-on acquisitions, expects CHF 90 million annualized savings and recurring profit improvement by year 4 from CHF 50 million of operational transformation investment, and will remain within its net debt-to-EBITDA corridor of 1x to 1.5x; no share buyback is being considered in the second half.

Sonova Holding AG Financial Statement Overview

Summary

The company showcases exceptional capital management and robust cash flow generation, highlighted by a low debt-to-equity ratio of 0.65 and converting 86% of net income into free cash flow. While expanding gross margins are a positive sign, recent top-line revenue contraction and stagnant net income growth present operational headwinds that temper the score.

Income Statement

68Positive

Balance Sheet

85Very Positive

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.63B3.61B3.87B3.63B3.74B3.36B
Gross Profit2.73B2.66B2.78B2.62B2.59B2.42B
EBITDA1.03B930.70M927.00M921.70M978.70M960.90M
Net Income494.65M430.60M540.50M601.00M647.50M649.00M
Balance Sheet
Total Assets5.88B5.63B5.92B5.79B5.55B5.59B
Cash, Cash Equivalents and Short-Term Investments672.15M722.10M687.10M513.80M414.80M612.00M
Total Debt1.74B1.71B1.76B1.79B1.81B1.48B
Total Liabilities3.09B2.99B3.24B3.30B3.32B3.16B
Stockholders Equity2.77B2.61B2.66B2.47B2.21B2.41B
Cash Flow
Free Cash Flow706.15M626.10M656.10M624.70M609.10M815.90M
Operating Cash Flow804.14M707.50M793.70M753.30M763.40M922.50M
Investing Cash Flow-108.72M-192.20M-212.70M-234.00M-429.50M-707.00M
Financing Cash Flow-506.56M-452.90M-401.80M-415.30M-523.50M-1.37B

Sonova Holding AG Technical Analysis

Technical Analysis SentimentPositive
Last Price68.29

Price Trends

50DMA63.26Positive
100DMA59.00Positive
200DMA53.49Positive

Market Momentum

MACD1.33Positive
RSI55.64Neutral
STOCH11.47Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Positive. The current price of 68.29 is below the 20-day moving average (MA) of 68.61, above the 50-day MA of 63.26, and above the 200-day MA of 53.49, indicating a neutral trend. The MACD of 1.33 indicates Positive momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 11.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SONVY.

Sonova Holding AG Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SONVY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.58B25.1510.60%2.78%9.77%12.28%
LIVNLIVN77Outperform$5.03B25.5115.35%―11.71%―
SONVYSONVY73Outperform$19.64B34.5218.27%1.70%0.68%2.45%
INSPINSP71Outperform$1.77B17.5512.49%―-0.19%131.98%
ABTABT67Neutral$187.95B40.199.11%2.32%10.00%-66.06%
COCHCOCH53Neutral$52.13M-1.80-9999.00%―11.06%64.70%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%SONVYABTMDTLIVNINSPCOCHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SONVY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SONVYSonova Holding Ag Unsponsored Adr68.2918.8238.05%
ABTAbbott Laboratories108.52-18.36-14.47%
MDTMedtronic102.869.6710.38%
LIVNLivaNova PLC91.3237.6870.25%
INSPInspire Medical61.10-23.77-28.01%
COCHEnvoy Medical, Inc. Class A6.740.213.28%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026